Huan Wang, PhD (she/her/hers)

Director of pharmacology and toxicology
TenNor Therapeutics (Suzhou) Ltd, China (People's Republic)

Disclosure(s): TenNor Therapeutics (Suzhou) Ltd: Employee

Dr. Huan Wang is the director of pharmacology and toxicology department of TenNor Therapeutics (Suzhou) Limited. Her current work involves non-clinical and responsible for external cooperation management. Dr. Wang graduated from Jilin Normal University (BS) and Nankai University (MS), received a PhD form the University of Notre Dame. Dr. Wang has 7+ years of experience in research and development of anti-infective products.

Poster(s):

• (P-1088) Safety Study of Rifaquizinone in Dogs Following Intra-articular Administration
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1089) Pharmacokinetics of Rifaquizinone in Rats and Dogs Following Intra-Articular Administration
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1090) Rifaquizinone for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Multicenter, Double-Blind, Randomized, Active-Controlled, Phase 2 Trial
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1097) Efficacy of Rifaquizinone in a Murine Model of Prosthetic Joint Infection (PJI) with Fluoroquinolone-Sensitive and -Resistant Staphylococcus aureus
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1111) Efficacy of Intra-Articular Administration of Rifaquizinone in Rodent Models of Implant Infection Associated with Staphylococcus aureus
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1116) Distribution of Rifaquizinone in Bone, Synovial Fluid and Plasma: A Phase 1 Trial in Patients Undergoing Total Hip or Knee Arthroplasty
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1117) An Open-label Phase 1 Study in Healthy Adult Male Participants to Investigate the Absorption, Metabolism, and Excretion of [¹⁴C]-Rifaquizinone Following a Single Intravenous Administration
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT